Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Beginning Cash Balance: 2010-2020

Historic Beginning Cash Balance for Northwest Biotherapeutics (NWBO) over the last 4 years, with Dec 2020 value amounting to $315,000.

  • Northwest Biotherapeutics' Beginning Cash Balance was N/A to $315,000 in Q4 2020 from the same period last year, while for Dec 2020 it was $749,000, marking a year-over-year change of. This contributed to the annual value of $379,000 for FY2020, which is 15.20% up from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Beginning Cash Balance of $315,000 as of Q4 2020, which was up 392.19% from $64,000 recorded in Q1 2020.
  • Northwest Biotherapeutics' Beginning Cash Balance's 5-year high stood at $764,000 during Q3 2017, with a 5-year trough of $41,000 in Q4 2018.
  • Moreover, its 3-year median value for Beginning Cash Balance was $282,500 (2018), whereas its average is $255,167.
  • Data for Northwest Biotherapeutics' Beginning Cash Balance shows a peak YoY increase of 254.67% (in 2018) and a maximum YoY decrease of 88.29% (in 2018) over the last 5 years.
  • Northwest Biotherapeutics' Beginning Cash Balance (Quarterly) stood at $350,000 in 2017, then slumped by 88.29% to $41,000 in 2018, then soared by 31.60% to $329,000 in 2019, then tumbled by 80.55% to $315,000 in 2020.
  • Its last three reported values are $315,000 in Q4 2020, $64,000 for Q1 2020, and $329,000 during Q1 2019.